Vinati Organics Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xu29pu10si2mfcfrdq08vesb.pdf

Key Takeaways


ATBS: The Destocking Drag & Recovery Bet

Vinati Saraf Mutreja: "We were told that in March that six months the destocking will go on. So I expect some recovery from October onwards."

New Products: The FY24 Bridge


Margins: Spreads Hold, But Mix Dilutes the Percentage

Vinati Saraf Mutreja: "Margin as a percentage of sales is very irrelevant because prices also fluctuate, when the price is low, what is fixed really the dollar per kg. So margin as a percentage of sales increases, but in a high price environment when RMCs are increasing margin as a percentage of sales comes down."

Pipeline: Anisole, MEHQ & Guaiacol Chemistry


Guidance & Commitments

CommitmentSpecificsTimeline
ATBS destocking recoveryRecovery from October onwards, per customer indications of six-month destocking from MarchQ3 FY24
Full-year salesClose at around ₹2,000 crores, with ~₹150 crores from antioxidants, provided the merger goes throughFY24
Next-year sales growth20% to 25% growth, driven by ATBS recovery plus AO and butyl phenol pickupFY25
Next-year antioxidant businessDouble to ~₹300 crores in salesFY25
Q2 performanceSimilar to Q1Q2 FY24
Full-year marginBelow 28%FY24
ATBS capacity expansionNew line from 40,000 to 60,000 MTPA completeEnd of FY24 or early FY25
VOPL plant commissioningCommissionedAround March 2024
Solar power expansionAdditional 11 MW commissionedSeptember 2023
NCLT merger approvalApproval hoped for before December; if not, alternative routes include withdrawing the scheme and doing an acquisition or leasing the plantBefore December 2023

Key Metrics

MetricQ1 FY24
Revenue from operations₹430 cr, vs ~₹500 cr in Q1 FY23
EBITDA₹109 cr, declined 15% to 17% YoY
PATDeclined 15% to 17% YoY
EBITDA margin~28%, maintained even in Q1
Revenue decline attribution90% due to lower volumes, 10% due to prices
ATBS revenue share~40% of total revenue
IBB revenue share~20% of total revenue
Butyl phenols revenue share~17% of total revenue
VAPL (antioxidants) plant utilization~25% of capacity
VAPL expected revenue for FY24~₹150 cr
FY24 revenue guidance (with merger)~₹2,000 cr, including ~₹150 cr from antioxidants
FY25 expected sales growth20% to 25%, with AO pickup, butyl phenol pickup, ATBS recovery
Full year FY24 margin guidanceBelow 28%, conservative due to lower-margin butyl phenols and AOs
ATBS capacity expansionFrom 40,000 to 60,000 metric tons per annum, completion expected end of FY24 or early next fiscal
VOPL capex~₹260 cr for MEHQ, Guaiacol, Iso Amylene derivatives, Anisoles; commissioning by March 2024